Endocrine Abstracts

Aim: Given the aggressive biological features of metastatic prostate cancer, a more aggressive treatment with [177Lu]-PSMA might be appropriate.Materials and methods: We have treated 15 patients (mean age 69 years) with intended 3 cycles of [177Lu]-PSMA every 4 weeks. All patients have been examined with [68Ga]-PSMA PET/MRI to validate PSMA expression of all metastatic lesions. We monitored haemoglobin (Hb), platelets (Pl), leucocytes and creatinine for ...